- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Harlan Krumholz, MD, Discusses Health Policy and Prevention
"There is often a disconnect between research and policy," said Harlan Krumholz, MD, Department of Internal Medicine/Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT.
"There is often a disconnect between research and policy," said Harlan Krumholz, MD, Department of Internal Medicine/Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT.
Dr Krumholz discusses the importance of research having a straight path into the policy process. Often, policy makers are isolated from researchers. Dr Krumholz says that we need to be able to bridge the gap between policy and research.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
